These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28232864)

  • 1. The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome.
    Humaidan P; Alviggi C; Fischer R; Esteves SC
    F1000Res; 2016; 5():2911. PubMed ID: 28232864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists.
    Esteves SC; Alviggi C; Humaidan P; Fischer R; Andersen CY; Conforti A; Bühler K; Sunkara SK; Polyzos NP; Galliano D; Grynberg M; Yarali H; Özbek IY; Roque M; Vuong LN; Banker M; Rienzi L; Vaiarelli A; Cimadomo D; Ubaldi FM
    Front Endocrinol (Lausanne); 2019; 10():814. PubMed ID: 31824427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept.
    Conforti A; Esteves SC; Picarelli S; Iorio G; Rania E; Zullo F; De Placido G; Alviggi C
    Panminerva Med; 2019 Mar; 61(1):24-29. PubMed ID: 30021418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgens Profile in Blood Serum and Follicular Fluid of Women With Poor Ovarian Response During Controlled Ovarian Stimulation Reveals Differences Amongst POSEIDON Stratification Groups: A Pilot Study.
    Fuentes A; Sequeira K; Tapia-Pizarro A; Muñoz A; Salinas A; Céspedes P; Escalona J; Godoy A
    Front Endocrinol (Lausanne); 2019; 10():458. PubMed ID: 31379738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why.
    Esteves SC; Roque M; Bedoschi GM; Conforti A; Humaidan P; Alviggi C
    Front Endocrinol (Lausanne); 2018; 9():461. PubMed ID: 30174650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification.
    Grisendi V; Mastellari E; La Marca A
    Front Endocrinol (Lausanne); 2019; 10():281. PubMed ID: 31139145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bologna vs. POSEIDON criteria as predictors of the likelihood of obtaining at least one euploid embryo in poor ovarian response: an analysis of 6,889 cycles.
    Reig A; Garcia-Velasco JA; Seli E
    Fertil Steril; 2023 Sep; 120(3 Pt 2):605-614. PubMed ID: 37187313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ART outcome in patients with poor ovarian response according to POSEIDON criteria.
    Lee HJ; Noh HK; Joo JK
    Sci Rep; 2022 Oct; 12(1):17723. PubMed ID: 36271137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live birth rates of low prognosis patients according to POSEIDON criteria; A retrospective cohort study.
    Seven B; Gulerman C; Ozgu-Erdinc AS; Yilmaz N; Engin-Ustun Y
    J Gynecol Obstet Hum Reprod; 2020 Sep; 49(7):101817. PubMed ID: 32428781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial.
    Xu Y; Nisenblat V; Lu C; Li R; Qiao J; Zhen X; Wang S
    Reprod Biol Endocrinol; 2018 Mar; 16(1):29. PubMed ID: 29587861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM
    Front Endocrinol (Lausanne); 2021; 12():630550. PubMed ID: 33790862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live birth rates in different subgroups of poor ovarian responders according to Bologna and POSEIDON group classification criteria.
    Mashayekhi M; Barabi F; Arabipoor A; Zolfaghari Z
    J Gynecol Obstet Hum Reprod; 2021 Nov; 50(9):102169. PubMed ID: 34044136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management Strategies for POSEIDON Groups 3 and 4.
    Haahr T; Dosouto C; Alviggi C; Esteves SC; Humaidan P
    Front Endocrinol (Lausanne); 2019; 10():614. PubMed ID: 31572298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cycles of
    Li Y; Li X; Yang X; Cai S; Lu G; Lin G; Humaidan P; Gong F
    Front Endocrinol (Lausanne); 2019; 10():642. PubMed ID: 31608011
    [No Abstract]   [Full Text] [Related]  

  • 15. High prevalence of low prognosis by the POSEIDON criteria in women undergoing planned oocyte cryopreservation.
    Horowitz E; Mizrachi Y; Barber E; Shimshy M; Levitas-Djerbi T; Finkelstein M; Shalev A; Farhi J; Raziel A; Esteves SC; Weissman A
    Eur J Obstet Gynecol Reprod Biol; 2024 Apr; 295():42-47. PubMed ID: 38335583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
    Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
    Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Women With an Unexpected Low Ovarian Response to Gonadotropin.
    Conforti A; Esteves SC; Cimadomo D; Vaiarelli A; Di Rella F; Ubaldi FM; Zullo F; De Placido G; Alviggi C
    Front Endocrinol (Lausanne); 2019; 10():387. PubMed ID: 31316461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Euploid blastocyst rates in patients from POSEIDON groups 3 and 4 using propensity score matching.
    Liu L; Cai B; Zhang X; Huang J; Zhou C
    Reprod Biomed Online; 2022 Aug; 45(2):374-383. PubMed ID: 35654685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative Live Birth Rates of Good and Low Prognosis Patients According to POSEIDON Criteria: A Single Center Analysis of 18,455 Treatment Cycles.
    Shi W; Zhou H; Tian L; Zhao Z; Zhang W; Shi J
    Front Endocrinol (Lausanne); 2019; 10():409. PubMed ID: 31293519
    [No Abstract]   [Full Text] [Related]  

  • 20. POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data research.
    Esteves SC; Yarali H; Vuong LN; Conforti A; Humaidan P; Alviggi C
    Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):159-187. PubMed ID: 35725717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.